FIGURE 6.

Serum cytokine levels in response to RvE1. Analysis of serum levels of interleukin (IL)-1α (a), IL-1β (b), IL-6 (c), and tumor necrosis factor (TNF)-α (d) showed that Veh-treated Ts65Dn mice had significantly higher levels relative to the NS cohorts. All cytokines were significantly reduced in Ts65Dn mice upon RvE1-treatment, whereas no treatment effect was observed in NS mice. (e) Two-way ANOVA analyses showed that the main effects were shared between karyotype and treatment. Tukey’s post hoc analysis confirmed that Veh-treated Ts65Dn mice had significantly higher levels of the four cytokines when compared to Veh-treated NS mice (IL-1α: p = .037, IL-1β: p = .017, IL-6: p < .001 and TNF-α: p < .001), and the RvE1 treatment significantly reduced the cytokine levels in Ts65Dn mice (IL-1α: p = .025, IL-1β: p = .013, IL-6: p = .011, and TNF-α: p < .001). All of the cytokines significantly correlated with NORT performance at both testing intervals. Tukey’s post hoc p values are shown for group comparisons and error bars represent mean ± SEM. NS, normosomic; NORT-DI, novel object recognition discrimination index; RvE1, resolvin E1; TNF-α, tumor necrosis factor-alpha; TS, Ts65Dn; Veh, vehicle